Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment

Cancer Cell

Volumn 31, Issue 2, 2017, Pages 194-207

  Katlinski, Kanstantsin V ^a   Gui, Jun ^a   Katlinskaya, Yuliya V ^a   Ortiz, Angelíca ^a   Chakraborty, Riddhita ^a   Bhattacharya, Sabyasachi ^a   Carbone, Christopher J ^a   Beiting, Daniel P ^a   Girondo, Melanie A ^b   Peck, Amy R ^b   Puré, Ellen ^a   Chatterji, Priya ^c   Rustgi, Anil K ^c   Diehl, J Alan ^d   Koumenis, Constantinos ^c   Rui, Hallgeir ^b   Fuchs, Serge Y ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

colorectal cancer; cytotoxic T cells; IFNAR1; immunosuppression; interferon; receptor; tumor microenvironment

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; INTERFERON RECEPTOR; TYPE 1 INTERFERON RECEPTOR; UNCLASSIFIED DRUG; ALPHA BETA INTERFERON RECEPTOR; IFNAR1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; STROMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOWN REGULATION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOWN-REGULATION; HUMANS; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 85012931658     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.01.004     Document Type: Article

References (55)

1. Aichele, P., Unsoeld, H., Koschella, M., Schweier, O., Kalinke, U., Vucikuja, S., CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J. Immunol. 176 (2006), 4525–4529.
2. Bhattacharya, S., Qian, J., Tzimas, C., Baker, D.P., Koumenis, C., Diehl, J.A., Fuchs, S.Y., Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor. J. Biol. Chem. 286 (2011), 22069–22076.
3. Bhattacharya, S., HuangFu, W.C., Dong, G., Qian, J., Baker, D.P., Karar, J., Koumenis, C., Diehl, J.A., Fuchs, S.Y., Anti-tumorigenic effects of type 1 interferon are subdued by integrated stress responses. Oncogene 32 (2013), 4214–4221.
4. Bhattacharya, S., Katlinski, K.V., Reichert, M., Takano, S., Brice, A., Zhao, B., Yu, Q., Zheng, H., Carbone, C.J., Katlinskaya, Y.V., et al. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol. Med. 6 (2014), 384–397.
5. Bidwell, B.N., Slaney, C.Y., Withana, N.P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N.E., Samarajiwa, S.A., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18 (2012), 1224–1231.
6. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
7. Chiba, T., Ohtani, H., Mizoi, T., Naito, Y., Sato, E., Nagura, H., Ohuchi, A., Ohuchi, K., Shiiba, K., Kurokawa, Y., Satomi, S., Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br. J. Cancer 91 (2004), 1711–1717.
8. Crouse, J., Bedenikovic, G., Wiesel, M., Ibberson, M., Xenarios, I., Von Laer, D., Kalinke, U., Vivier, E., Jonjic, S., Oxenius, A., Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity 40 (2014), 961–973.
9. Curtsinger, J.M., Valenzuela, J.O., Agarwal, P., Lins, D., Mescher, M.F., Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174 (2005), 4465–4469.
10. Curtsinger, J.M., Gerner, M.Y., Lins, D.C., Mescher, M.F., Signal 3 availability limits the CD8 T cell response to a solid tumor. J. Immunol. 178 (2007), 6752–6760.
11. Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Archambault, J.M., Lee, H., Arthur, C.D., White, J.M., Kalinke, U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208 (2011), 1989–2003.
12. Fearon, D.T., The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol. Res. 2 (2014), 187–193.
13. Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S., Connell, C.M., Roberts, E.W., Zhao, Q., Caballero, O.L., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110 (2013), 20212–20217.
14. Fuchs, S.Y., Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J. Interferon Cytokine Res. 33 (2013), 211–225.
15. Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M., Gajewski, T.F., Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 208 (2011), 2005–2016.
16. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
17. Gilham, D.E., Debets, R., Pule, M., Hawkins, R.E., Abken, H., CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol. Med. 18 (2012), 377–384.
18. Hellström, I., Hellström, K.E., Pierce, G.E., Yang, J.P., Cellular and humoral immunity to different types of human neoplasms. Nature 220 (1968), 1352–1354.
19. Hervas-Stubbs, S., Riezu-Boj, J.I., Gonzalez, I., Mancheno, U., Dubrot, J., Azpilicueta, A., Gabari, I., Palazon, A., Aranguren, A., Ruiz, J., et al. Effects of IFN-α as a signal-3 cytokine on human naive and antigen-experienced CD8(+) T cells. Eur. J. Immunol. 40 (2010), 3389–3402.
20. Hervas-Stubbs, S., Mancheno, U., Riezu-Boj, J.I., Larraga, A., Ochoa, M.C., Alignani, D., Alfaro, C., Morales-Kastresana, A., Gonzalez, I., Larrea, E., et al. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J. Immunol. 189 (2012), 3299–3310.
21. Hildner, K., Edelson, B.T., Purtha, W.E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B.U., Unanue, E.R., Diamond, M.S., et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322 (2008), 1097–1100.
22. Hiroishi, K., Tuting, T., Lotze, M.T., IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J. Immunol. 164 (2000), 567–572.
23. Huangfu, W.C., Qian, J., Liu, C., Liu, J., Lokshin, A.E., Baker, D.P., Rui, H., Fuchs, S.Y., Inflammatory signaling compromises cell responses to interferon alpha. Oncogene 31 (2012), 161–172.
24. Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348 (2015), 74–80.
25. Katlinskaya, Y.V., Katlinski, K.V., Yu, Q., Ortiz, A., Beiting, D.P., Brice, A., Davar, D., Sanders, C., Kirkwood, J.M., Rui, H., et al. Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression. Cell Rep 15 (2016), 171–180.
26. Klemm, F., Joyce, J.A., Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 25 (2015), 198–213.
27. Kolumam, G.A., Thomas, S., Thompson, L.J., Sprent, J., Murali-Krishna, K., Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202 (2005), 637–650.
28. Kumar, K.G., Tang, W., Ravindranath, A.K., Clark, W.A., Croze, E., Fuchs, S.Y., SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 22 (2003), 5480–5490.
29. Le Bon, A., Tough, D.F., Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14 (2002), 432–436.
30. Liu, J., HuangFu, W.C., Kumar, K.G., Qian, J., Casey, J.P., Hamanaka, R.B., Grigoriadou, C., Aldabe, R., Diehl, J.A., Fuchs, S.Y., Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe 5 (2009), 72–83.
31. Marotta, D., Karar, J., Jenkins, W.T., Kumanova, M., Jenkins, K.W., Tobias, J.W., Baldwin, D., Hatzigeorgiou, A., Alexiou, P., Evans, S.M., et al. In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Res. 71 (2011), 779–789.
32. Mostafavi, S., Yoshida, H., Moodley, D., LeBoite, H., Rothamel, K., Raj, T., Ye, C.J., Chevrier, N., Zhang, S.Y., Feng, T., et al. Parsing the interferon transcriptional network and its disease associations. Cell 164 (2016), 564–578.
33. Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., Ohtani, H., CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58 (1998), 3491–3494.
34. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005), 375–386.
35. Qian, J., Zheng, H., Huangfu, W.C., Liu, J., Carbone, C.J., Leu, N.A., Baker, D.P., Fuchs, S.Y., Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1. PLoS Pathog., 7, 2011, e1002065.
36. Quail, D.F., Joyce, J.A., Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19 (2013), 1423–1437.
37. Rohr, C., Kerick, M., Fischer, A., Kuhn, A., Kashofer, K., Timmermann, B., Daskalaki, A., Meinel, T., Drichel, D., Borno, S.T., et al. High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS One, 8, 2013, e67461.
38. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
39. Rusinova, I., Forster, S., Yu, S., Kannan, A., Masse, M., Cumming, H., Chapman, R., Hertzog, P.J., Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41 (2013), D1040–D1046.
40. Santini, S.M., Lapenta, C., Santodonato, L., D'Agostino, G., Belardelli, F., Ferrantini, M., IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb. Exp. Pharmacol., 2009, 295–317.
41. Sarantopoulos, J., Shapiro, G.I., Cohen, R.B., Clark, J.W., Kauh, J.S., Weiss, G.J., Cleary, J.M., Mahalingam, D., Pickard, M.D., Faessel, H.M., et al. Phase I study of the investigational NEDD8-activating enzyme inhibitor Pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors. Clin. Cancer Res. 22 (2015), 847–857.
42. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
43. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remedios, C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20 (2014), 1301–1309.
44. Stewart, C.A., Metheny, H., Iida, N., Smith, L., Hanson, M., Steinhagen, F., Leighty, R.M., Roers, A., Karp, C.L., Muller, W., Trinchieri, G., Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J. Clin. Invest. 123 (2013), 4859–4874.
45. Talmadge, J.E., Donkor, M., Scholar, E., Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 26 (2007), 373–400.
46. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
47. Trinchieri, G., Type I interferon: friend or foe?. J. Exp. Med. 207 (2010), 2053–2063.
48. Uze, G., Schreiber, G., Piehler, J., Pellegrini, S., The receptor of the type I interferon family. Curr. Top. Microbiol. Immunol. 316 (2007), 71–95.
49. Wang, Y., Swiecki, M., Cella, M., Alber, G., Schreiber, R.D., Gilfillan, S., Colonna, M., Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 11 (2012), 631–642.
50. Wang, L.C., Lo, A., Scholler, J., Sun, J., Majumdar, R.S., Kapoor, V., Antzis, M., Cotner, C.E., Johnson, L.A., Durham, A.C., et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2 (2014), 154–166.
51. Xu, H.C., Grusdat, M., Pandyra, A.A., Polz, R., Huang, J., Sharma, P., Deenen, R., Kohrer, K., Rahbar, R., Diefenbach, A., et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity 40 (2014), 949–960.
52. Zhao, Z., Condomines, M., van der Stegen, S.J., Perna, F., Kloss, C.C., Gunset, G., Plotkin, J., Sadelain, M., Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28 (2015), 415–428.
53. Zheng, H., Qian, J., Carbone, C.J., Leu, N.A., Baker, D.P., Fuchs, S.Y., Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood 118 (2011), 4003–4006.
54. Zhou, P., Shaffer, D.R., Alvarez Arias, D.A., Nakazaki, Y., Pos, W., Torres, A.J., Cremasco, V., Dougan, S.K., Cowley, G.S., Elpek, K., et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 506 (2014), 52–57.
55. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15 (2015), 405–414.